Instead, the administration of CAR-T cells with an affinity-tuned anti-PSCA CAR and an anti-PSMA CCR resulted in the eradication of only double-positive (PSCA+PSMA+) prostate cancer cells. The gene discussed is FOLH1; the disease is prostate cancer.